Quoin Pharmaceuticals Ltd. Operating Cash Flow
Quoin Pharmaceuticals Ltd. (QNRX) reported Operating Cash Flow of -$8.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.14M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.87M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.04M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.23M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2025 was -$13.54M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2024 was -$7.86M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2023 was -$7.86M.
- Quoin Pharmaceuticals Ltd. net cash provided by (used in) operating activities for fiscal 2022 was -$8.48M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.01M 10-Q · filed 2026-08-14 | -$13.05M derived: sum of 3 quarters · filed 2026-08-14 | -$15.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$4.87M 10-Q · filed 2026-05-07 | -$9.90M derived: sum of 2 quarters · filed 2026-05-07 | -$12.13M derived: sum of 3 quarters · filed 2026-05-07 | -$15.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$7.26M derived: sum of 2 quarters · filed 2026-03-26 | -$10.95M derived: sum of 3 quarters · filed 2026-08-14 | -$13.54M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.91M derived: sum of 2 quarters · filed 2026-08-14 | -$8.51M 10-Q · filed 2025-11-06 | -$10.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$6.28M 10-Q · filed 2026-08-14 | -$8.52M derived: sum of 3 quarters · filed 2026-08-14 | -$10.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$2.59M 10-Q · filed 2026-05-07 | -$4.83M derived: sum of 2 quarters · filed 2026-05-07 | -$7.01M derived: sum of 3 quarters · filed 2026-05-07 | -$9.02M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$4.42M derived: sum of 2 quarters · filed 2026-03-26 | -$6.42M derived: sum of 3 quarters · filed 2026-03-26 | -$7.86M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.19M derived: sum of 2 quarters · filed 2025-11-06 | -$5.62M 10-Q · filed 2025-11-06 | -$8.84M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$3.44M 10-Q · filed 2025-08-07 | -$6.67M derived: sum of 3 quarters · filed 2025-08-07 | -$7.99M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.43M 10-Q · filed 2025-05-13 | -$4.66M derived: sum of 2 quarters · filed 2025-05-13 | -$5.98M derived: sum of 3 quarters · filed 2025-05-13 | -$7.55M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$4.55M derived: sum of 2 quarters · filed 2025-03-13 | -$6.12M derived: sum of 3 quarters · filed 2025-03-13 | -$7.86M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.89M derived: sum of 2 quarters · filed 2024-11-08 | -$4.64M 10-Q · filed 2024-11-08 | -$6.58M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.32M 10-Q · filed 2024-08-08 | -$5.26M derived: sum of 3 quarters · filed 2024-08-08 | -$7.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.75M 10-Q · filed 2024-05-09 | -$3.69M derived: sum of 2 quarters · filed 2024-05-09 | -$5.98M derived: sum of 3 quarters · filed 2024-05-09 | -$8.13M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$4.24M derived: sum of 2 quarters · filed 2024-03-14 | -$6.39M derived: sum of 3 quarters · filed 2024-03-14 | -$8.48M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$4.44M derived: sum of 2 quarters · filed 2023-11-09 | -$6.54M 10-Q · filed 2023-11-09 | -$9.72M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.24M 10-Q · filed 2023-08-03 | -$7.42M derived: sum of 3 quarters · filed 2023-08-03 | -$8.33M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$2.09M 10-Q · filed 2023-05-09 | -$5.27M derived: sum of 2 quarters · filed 2023-05-09 | -$6.18M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$3.18M derived: 10-K 12 month − 6-K 9 month · filed 2023-03-15 | -$4.09M derived: sum of 2 quarters · filed 2023-03-15 | -$5.72M 10-K · filed 2023-03-15 | |
| 2021-09-30 | -$907.54K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-10 | -$2.54M 6-K · filed 2022-11-10 | ||
| 2021-06-30 | -$1.63M 6-K · filed 2022-08-18 | |||
| 2020-12-31 | -$1.34M 20-F · filed 2022-04-14 | |||
| 2019-12-31 | -$1.30M 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |